The Novel Excipient Pilot Program
A major regulatory milestone in 2026 is the expansion of the FDA’s Novel Excipient Review Pilot Program. Traditionally, pharmaceutical companies were afraid to use "new" excipients because they weren't pre-approved, creating a cycle of stagnant innovation.
Under the 2026 guidelines, excipient manufacturers can submit their new molecules for safety review independently of a specific drug application. This has unlocked a wave of innovation in high-concentration subcutaneous delivery, allowing patients to self-inject large doses of medication at home that previously required hours-long hospital IV infusions.
1 View
